Login to Your Account

Other News to Note

Wednesday, January 29, 2014

Takeda Pharmaceutical Co. Ltd., of Osaka, Japan, said Takeda Development Center Shanghai and Takeda Development Center Asia Pte. Ltd. started the Phase III TOURMALINE-MM1 global study with the oral proteasome inhibitor, ixazomib, in relapsed and/or refractory multiple myeloma.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription